To explore the value of targeting GSDME for improving the sensitivity of HCC to Lenvatinib treatment, we constructed a mouse subcutaneous xenograft model using PLC/PRF/5 cells that stably overexpress GSDME and SK-Hep-1cells with GSDME knockdown. This evidence concerns the gene GSDME and hepatocellular carcinoma.